Table 7 Concentrations of miRNAs in patients with and without acute kidney injury on day 7
Group | miRNA | No AKI | AKI | Â | ||
|---|---|---|---|---|---|---|
| Â | Â | Median | IQR | Median | IQR | P |
Vancomycin | hsa-miR-15a-5p (amol/L) | 132.7 | 105.9–228.2 | 228.4 | 144.9–368.3 | 0.229 |
hsa-miR-155-5p (amol/L) | 4.3 | 3.7–4.7 | 7.4 | 3.5–26.6 | 0.400 | |
hsa-miR-192-5p (amol/L) | 21.4 | 10.4–68.6 | 96.8 | 69.9–101.8 | 0.114 | |
hsa-miR-423-5p (amol/L) | 640.4 | 407.5–895.0 | 1004.0 | 768.5–3313.0 | 0.229 | |
Gentamicin | hsa-miR-15a-5p (amol/L) | 274.7 | 125.5–467.0 | 109.6 | 75.1–182.6 | 0.013 |
hsa-miR-155-5p (amol/L) | 4.5 | 3.0–5.8 | 5.5 | 4.2–6.5 | 0.182 | |
hsa-miR-192-5p (amol/L) | 33.4 | 25.1–62.7 | 30.4 | 10.9–63.9 | 0.824 | |
hsa-miR-423-5p (amol/L) | 1024.0 | 517.2–1156.0 | 1016.0 | 634.9–1651 | 0.552 | |
oATB | hsa-miR-15a-5p (amol/L) | 171.2 | 137.4–292.0 | 277.8 | 222.0–432.6 | 0.299 |
hsa-miR-155-5p (amol/L) | 4.9 | 3.7–6.9 | 6.9 | 4.4–10.0 | 0.270 | |
hsa-miR-192-5p (amol/L) | 32.8 | 26.4–85.3 | 81.9 | 34.6–125.6 | 0.227 | |
hsa-miR-423-5p (amol/L) | 668.7 | 513.3–973.1 | 812.0 | 493.3–2358.0 | 0.592 | |